FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149331300> ?p ?o ?g. }

• W2149331300 endingPage "8730" @default.
• W2149331300 startingPage "8722" @default.
• W2149331300 abstract "Malignant gliomas are highly proliferative and angiogenic cancers resistant to conventional therapies. Although RAS and RAF mutations are uncommon in gliomas, RAS activity is increased in gliomas. Additionally, vascular endothelial growth factor and its cognate receptors are highly expressed in gliomas. We now report that AAL881, a novel low-molecular weight inhibitor of the kinase activities associated with B-RAF, C-RAF (RAF-1), and VEGF receptor-2 (VEGFR2), showed activity against glioma cell lines and xenografts. In culture, AAL881 inhibited the downstream effectors of RAF in a concentration-dependent manner, with inhibition of proliferation associated with a G(1) cell cycle arrest, induction of apoptosis, and decreased colony formation. AAL881 decreased the proliferation of bovine aortic endothelial cells as well as the tumor cell secretion of vascular endothelial growth factor and inhibited the invasion of glioma cells through an artificial extracellular matrix. Orally administered AAL881 was well tolerated with minimal weight loss in non-tumor-bearing mice. Established s.c. human malignant glioma xenografts grown in immunocompromised mice treated with a 10-day course of oral AAL881 exhibited growth delays relative to control tumors, frequently resulting in long-term complete regressions. AAL881 treatment extended the survival of immunocompromised mice bearing orthotopic glioma xenografts compared with placebo controls. The intraparenchymal portions of orthotopic AAL881-treated tumors underwent widespread necrosis consistent with vascular disruption compared with the subarachnoid elements. These effects are distinct from our prior experience with VEGFR2 inhibitors, suggesting that targeting RAF itself or in combination with VEGFR2 induces profound tumor responses in gliomas and may serve as a novel therapeutic approach in patients with malignant gliomas." @default.
• W2149331300 created "2016-06-24" @default.
• W2149331300 creator A5004814459 @default.
• W2149331300 creator A5021296578 @default.
• W2149331300 creator A5023156067 @default.
• W2149331300 creator A5025528414 @default.
• W2149331300 creator A5044496405 @default.
• W2149331300 creator A5051383827 @default.
• W2149331300 creator A5055252730 @default.
• W2149331300 creator A5057371623 @default.
• W2149331300 creator A5059327760 @default.
• W2149331300 creator A5060208068 @default.
• W2149331300 creator A5061834369 @default.
• W2149331300 creator A5073862375 @default.
• W2149331300 creator A5085537336 @default.
• W2149331300 date "2006-09-01" @default.
• W2149331300 modified "2023-10-15" @default.
• W2149331300 title "AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma" @default.
• W2149331300 cites W135857521 @default.
• W2149331300 cites W1537447319 @default.
• W2149331300 cites W1556933114 @default.
• W2149331300 cites W1562223973 @default.
• W2149331300 cites W1573479107 @default.
• W2149331300 cites W1603973043 @default.
• W2149331300 cites W1655331233 @default.
• W2149331300 cites W1966726954 @default.
• W2149331300 cites W1969998496 @default.
• W2149331300 cites W1972024414 @default.
• W2149331300 cites W1973055017 @default.
• W2149331300 cites W1983064145 @default.
• W2149331300 cites W1985471352 @default.
• W2149331300 cites W1995255940 @default.
• W2149331300 cites W2002424169 @default.
• W2149331300 cites W2005298886 @default.
• W2149331300 cites W2010677999 @default.
• W2149331300 cites W2014018734 @default.
• W2149331300 cites W2020451386 @default.
• W2149331300 cites W2028415754 @default.
• W2149331300 cites W2036082581 @default.
• W2149331300 cites W2037480365 @default.
• W2149331300 cites W2043487198 @default.
• W2149331300 cites W2044351212 @default.
• W2149331300 cites W2072928113 @default.
• W2149331300 cites W2080719056 @default.
• W2149331300 cites W2108760239 @default.
• W2149331300 cites W2114098415 @default.
• W2149331300 cites W2116177733 @default.
• W2149331300 cites W2125096000 @default.
• W2149331300 cites W2135439671 @default.
• W2149331300 cites W2140765540 @default.
• W2149331300 cites W2145616602 @default.
• W2149331300 cites W2157774521 @default.
• W2149331300 cites W2163188200 @default.
• W2149331300 cites W2165057712 @default.
• W2149331300 cites W2169444383 @default.
• W2149331300 cites W2170285778 @default.
• W2149331300 cites W2170665695 @default.
• W2149331300 cites W2170925157 @default.
• W2149331300 cites W2316684085 @default.
• W2149331300 cites W2318572606 @default.
• W2149331300 cites W2322386893 @default.
• W2149331300 doi "https://doi.org/10.1158/0008-5472.can-06-0284" @default.
• W2149331300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16951188" @default.
• W2149331300 hasPublicationYear "2006" @default.
• W2149331300 type Work @default.
• W2149331300 sameAs 2149331300 @default.
• W2149331300 citedByCount "48" @default.
• W2149331300 countsByYear W21493313002012 @default.
• W2149331300 countsByYear W21493313002013 @default.
• W2149331300 countsByYear W21493313002014 @default.
• W2149331300 countsByYear W21493313002017 @default.
• W2149331300 countsByYear W21493313002019 @default.
• W2149331300 countsByYear W21493313002023 @default.
• W2149331300 crossrefType "journal-article" @default.
• W2149331300 hasAuthorship W2149331300A5004814459 @default.
• W2149331300 hasAuthorship W2149331300A5021296578 @default.
• W2149331300 hasAuthorship W2149331300A5023156067 @default.
• W2149331300 hasAuthorship W2149331300A5025528414 @default.
• W2149331300 hasAuthorship W2149331300A5044496405 @default.
• W2149331300 hasAuthorship W2149331300A5051383827 @default.
• W2149331300 hasAuthorship W2149331300A5055252730 @default.
• W2149331300 hasAuthorship W2149331300A5057371623 @default.
• W2149331300 hasAuthorship W2149331300A5059327760 @default.
• W2149331300 hasAuthorship W2149331300A5060208068 @default.
• W2149331300 hasAuthorship W2149331300A5061834369 @default.
• W2149331300 hasAuthorship W2149331300A5073862375 @default.
• W2149331300 hasAuthorship W2149331300A5085537336 @default.
• W2149331300 hasConcept C126322002 @default.
• W2149331300 hasConcept C146285616 @default.
• W2149331300 hasConcept C14858245 @default.
• W2149331300 hasConcept C150710994 @default.
• W2149331300 hasConcept C167734588 @default.
• W2149331300 hasConcept C170493617 @default.
• W2149331300 hasConcept C2777025900 @default.
• W2149331300 hasConcept C2778227246 @default.
• W2149331300 hasConcept C502942594 @default.
• W2149331300 hasConcept C71924100 @default.
• W2149331300 hasConcept C86803240 @default.

• next